FIELD: medicine.
SUBSTANCE: method involves applying N-bisphosphonates like Zoledronic acid and its derivatives for prolonged inhibiting bone tissue resorption in states distinguished by increased bone tissue renewal like it occurs in osteoporosis cases by periodically administering the drug at a dose of 2 to 10 mg. Pauses between drug introductions have become longer when compared to periodicity considered to be required in earlier times, while being greater than 6 months.
EFFECT: enhanced effectiveness of treatment.
10 cl, 1 tbl
